Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Net Income (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Net Income for 8 consecutive years, with -$17.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 41.06% to -$17.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$103.2 million, a 67.25% decrease, with the full-year FY2024 number at -$63.7 million, up 3.15% from a year prior.
  • Net Income was -$17.7 million for Q3 2025 at Whitehawk Therapeutics, up from -$52.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$1.5 million in Q2 2021 to a low of -$87.1 million in Q3 2021.
  • A 5-year average of -$20.3 million and a median of -$16.0 million in 2021 define the central range for Net Income.
  • Peak YoY movement for Net Income: crashed 1386.04% in 2021, then surged 83.38% in 2022.
  • Whitehawk Therapeutics' Net Income stood at -$16.0 million in 2021, then grew by 12.99% to -$13.9 million in 2022, then fell by 16.93% to -$16.3 million in 2023, then decreased by 12.32% to -$18.3 million in 2024, then rose by 3.16% to -$17.7 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Net Income are -$17.7 million (Q3 2025), -$52.8 million (Q2 2025), and -$14.4 million (Q1 2025).